Apatinib Plus Toripalimab (Anti-PD1 Therapy) as Second-Line Therapy in Patients With Advanced Gastric or Esophagogastric Junction Cancer: Results From a Randomized, Open-Label Phase II StudyQing Wei, Jieer Ying, Weijun Chen et al.|The Oncologist|2024Cited by 10
Multi-omics analysis uncovers predictive biomarkers for the efficacy and outcomes of chemoimmunotherapy in advanced unresectable biliary tract cancersJiaojiao Ni, Jieer Ying, Chaoqun Li et al.|BMC Medicine|2025Cited by 7